Diligence memo · auto-generated · as of July 2, 2026
Click Therapeutics, Inc.
Click Therapeutics, Inc. looks fair against its niche peers and is active on financing cadence.
Businessfiled
Click Therapeutics, Inc. operates in Pharma, based in NEW YORK.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Click Therapeutics, Inc. has raised $137M in disclosed capital across 9 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $52M on 2021-10-21.
Most recent recorded round closed around 2025-03-17.
Valuation (modeled)modeled
Provath models Click Therapeutics, Inc. at approximately $332M (range $158M–$458M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.09× the median modeled value of Series C Pharma companies in 2025–2027 (6 peers) — value vs value, same stage and era. Within the normal band (109% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 16 months.
Last raise 16 mo ago; this sector typically re-raises about every 16 months.
Raising on or ahead of the sector's normal rhythm.
The last round stepped up 5.9× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 94% of Pharma peers (310 compared).
Modeled value ranks above 83% of those peers.
Closest niche peers: Allay Therapeutics, Inc., Somite Therapeutics, Inc., Indapta Therapeutics Inc., Pheast Therapeutics, Inc., Bryn Pharma, LLC.
Peoplefiled
24 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.